N/A
Manufactured by Organon LLC
35,067 FDA adverse event reports analyzed
Last updated: 2026-04-14
MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Organon LLC. The most commonly reported adverse reactions for MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE include PRODUCT QUALITY ISSUE, NO ADVERSE EVENT, DRUG DOSE OMISSION, DYSPNOEA, POOR QUALITY DEVICE USED. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE.
Out of 15,238 classified reports for MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 35,067 FDA FAERS reports that mention MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include PRODUCT QUALITY ISSUE, NO ADVERSE EVENT, DRUG DOSE OMISSION, DYSPNOEA, POOR QUALITY DEVICE USED, COUGH. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Organon LLC in connection with MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE. Always verify the specific product and NDC with your pharmacist.